In the TME of HCC patients, the Kla modification of insulin-like growth factor binding protein 3 (IGFBP3), the m6A reader YTH domain family protein 2 (YTHDF2) binding protein, can enhance its interaction with the mRNAs of PCK2 and NRF2, thereby transactivating the genes to promote lenvatinib resistance [156]. The gene discussed is IGFBP3; the disease is hepatocellular carcinoma.